



Multiple Myeloma Research Foundation 2026 Research Fellowship Award

Program Guidelines and Application



2026 RESEARCH FELLOWSHIP PROGRAM

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over \$500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmr.org.

Program Description:

The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2026 Research Fellowship Program, an initiative supporting early career researchers at the post-doctorate, medical fellow, or junior faculty levels currently active or interested in research in multiple myeloma. The goal of this initiative is to engage and support early career investigators interested in basic and clinical research focused on multiple myeloma and its precursor conditions, with the goal of advancing our understanding of myeloma disease biology, disease risk, and treatment response and relapse. This program will provide up to **\$75,000** of financial support for **one (1) year** to successful applicants. This amount includes both research costs and applicable indirect costs. Furthermore, to encourage the submission of highly innovative proposals, the MMRF may also be able to provide applicants with additional support to mitigate technical and institutional infrastructure barriers (e.g., technology and analytical platforms) via access to the MMRF's partner institutions and laboratories.

Key Dates:

- **Friday, May 1st, 2026 – Request for Applications (RFA) issued**
- **Wednesday, July 15th, 2026 – Deadline for Submission of Applications**
- **Thursday, October 1st, 2026 – Applicant notification**
- **Monday, November 30th, 2026 – Deadline for Contract signatures**
- **Funding Period: January-December 2027**

**Background:**

Multiple myeloma is a plasma cell malignancy which is currently not curable but is a treatable disease. In the United States alone, approximately 30,000 new cases will be diagnosed this year and nearly 12,500 people will die from this disease.

Significant advances in our understanding of the pathophysiology and molecular biology of multiple myeloma and precursor conditions (MGUS, SMM) have identified numerous molecular events associated with disease development and progression. These findings have led to improved understanding of disease risk and the development of new therapies for the treatment of multiple myeloma. However, to fully leverage the current armamentarium of therapeutic options and maximize clinical benefit, we still need to understand how to best optimize therapy and the sequence of therapies to tailor treatment for the individual patient and their unique disease.

It is important to note that the prevalence of myeloma and reported clinical outcomes is not equal across all patient groups. Multiple myeloma and its precursor conditions disproportionately affect the Black population relative to other populations. There is an approximately 3x-higher incidence of active myeloma and a 4x-higher incidence of MGUS in the Black population compared with the White population, and the onset of disease occurs approximately 10 years earlier for Black individuals. Although there is evidence of genetic, immunological, and environmental factors to explain these differences, the underlying molecular and cellular mechanisms are not fully understood.

Most myeloma patients will relapse on therapy, and consequently, undergo more aggressive therapy with the likelihood of shortened duration of clinical response. Therefore, there continues to be a need for new, novel therapies and drug combinations targeting the mechanisms that drive disease biology and drug resistance. This requires researchers to further dissect the molecular and cellular basis of disease development and progression, response to therapy, mechanisms of drug relapse, and to develop new tools and technologies to monitor for and intercept these events.

The MMRF is currently seeking applications for the Research Fellowship Program focused on multiple myeloma disease biology and genomics, with an emphasis on clinical outcomes.



Eligibility:

Applications for the 2026 MMRF Research Fellowship Program are requested from researchers at academic and not-for-profit research institutions in the United States and worldwide. The MMRF Fellowship Program does NOT require applicants to be US citizens.

Note: Due to US Federal regulations preventing data-sharing with the MMRF, the MMRF cannot accept applications from researchers at Federal Research Institutions (e.g., National Institutes of Health, National Cancer Institute).

Researchers with a Ph.D., M.D. or equivalent degree at the post-doctoral, clinical fellow, or junior faculty level are encouraged to apply.

The following conditions must be met by all applicants:

- Post-doctoral and medical fellows applying for the award must work under the supervision of a research mentor in the multiple myeloma field.
- The MMRF Fellowship program is targeted to early career scientists. Applicants must have obtained their highest degree within 10 years of the application date.
- Applicants may not hold a position higher than Assistant Professor.
- Applicants who are beginning studies in the multiple myeloma field must have a research sponsor/mentor at their institution who is active in the multiple myeloma field and who can provide guidance to the applicant in the proposed area of research.

The MMRF is committed to providing funding opportunities for Black, Indigenous, and People of Color (BIPOC) scientists and clinicians interested in multiple myeloma research. We **strongly encourage** BIPOC researchers to apply for the MMRF Research Fellowship program.



Funds Available:

The total cost of this award may not exceed \$75,000. This amount includes all research costs and applicable indirect costs, which cannot exceed 10% of total direct costs (\$6,818.18). No extensions are permitted beyond the one-year funding period. Awards will be rescinded if contract signatures are not completed by November 30th, 2026.

(a) Permissible Costs

- a. Salary for the Principal Investigator that has a faculty appointment (i.e., Instructor, Professor, etc.,) with the following restrictions:
 - i. the percent salary (with fringe benefits) cannot exceed the percent effort set forth in the Approved Budget.
 - ii. the salary request (with fringe benefits) cannot exceed forty percent (40%) of the total grant request.
- b. Salaries for the Principal Investigator or professional staff that do not have faculty appointments and technical assistants as necessary with the following restrictions:
 - i. the percent salary (with fringe benefits) cannot exceed the percent effort set forth in the Approved Budget.
 - ii. the salary request (with fringe benefits) cannot exceed forty percent (40 %) of the total grant request.
 - iii. Salary of other participants in the Grant Research that have faculty appointments (i.e., Instructor, Professor, etc.,).
 1. the percent salary (with fringe benefits) cannot exceed the percent effort set forth in the Approved Budget.
 2. the salary request (with fringe benefits) cannot exceed forty percent (40%) of the total grant request.
 - iv. Minimal but essential permanent equipment which is directly relevant to the Grant Research.
 - v. Publication costs up to a maximum of one thousand dollars (\$1,000.00).
 - vi. Expendable supplies.
 - vii. Other expenses directly related to the conduct of Grant Research.
 - viii. Travel to attend scientific meetings that are directly related to the Grant Research. Such travel arrangements shall be subject to the prior written approval of the MMRF and shall not exceed one thousand five-hundred dollars (\$1,500).
 - ix. Indirect operating costs incurred by the Sponsoring Institution during the Grant Term in an amount **not to exceed ten percent (10%)** of the total direct costs.



- x. Notwithstanding the foregoing, in no event shall the base salary exceed the annual Federal capitation imposed by the National Institutes of Health.

(b) Impermissible Costs

- a. Construction, alteration, maintenance or rental of buildings or building space.
- b. Computer equipment, office equipment, and furniture.
- c. Dues for membership in scientific societies.
- d. Office supplies including, but not limited to, mail/postage costs, copying costs, telephone, fax, internet access, or other similar costs.
- e. Tuition, books, and journals.
- f. Significant Equipment costs.
- g. Any other costs not specifically permitted under Permissible Costs.

The funds awarded shall be used solely for the purposes specified in the application submitted to the MMRF as executed by the Principal Investigator, collaborating staff, and institution in compliance with the budget annexed to the application.

No extensions are offered beyond the funding period. The MMRF expects one end of year report summarizing work supported by the grant.



Application and Review Process:

All applications are due Wednesday, July 15, 2026 at 11:59 PM EDT and **must** be submitted via email to grants@themmrf.org. No paper applications will be accepted.

Research Fellowship applications are reviewed by external experts using the National Institutes of Health (NIH) scoring system of 1 (highest) to 9 (lowest). Each proposal will be scored by two reviewers and scores will be averaged for a final score. Reviewers weigh the promise of each proposal with previous accomplishments of the applicant, the probability of meaningful results, and the likely contribution of the research to advance knowledge of myeloma disease biology, diagnosis, and treatment. In addition, support by a research mentor or sponsor must be adequately demonstrated. The objectives of the proposal must also be reasonable to be performed over the one-year grant period.

MMRF will notify all applicants of the outcome of their grant application in October 2026.

How to submit the application:

All applications must be electronically submitted via email to grants@themmrf.org. All application instructions are provided below.

For all scientific and administrative inquiries, please contact **Chaitanya (Chuck) Acharya, PhD** and **Steven Foltz, PhD** via email at grants@themmrf.org.



CONTRACTING AND TERMS OF AWARD:

Successful applicants whose proposals are selected for the MMRF Research Fellowship will be issued with a Notice of Award. The successful applicant(s) will provide the MMRF with the name and contact information for a legal representative authorized to negotiate with the MMRF on behalf of their institution. The MMRF reserves the right to withdraw an award if the parties fail to agree to terms within sixty (60) days of the Notice of Award.

Failure of applicants and/or their sponsoring institutions to adhere to any of the terms and conditions in the contract shall constitute sufficient grounds for the MMRF, in its discretion, to withhold support until the deficiency is corrected. If the deficiency cannot be corrected, the MMRF or the sponsoring institution may terminate the contract upon giving thirty (60) days written notice.

The following terms and conditions are not negotiable. By submitting an application, you are acknowledging that if your application is successful, these terms will need to be approved. MMRF recommends that applicants speak with their grants and contracting offices prior to applying.

<p>Funding</p>	<ul style="list-style-type: none"> • Funding for Fellowship Grant is \$75,000 • Overhead is included in the Grant amount and shall not exceed 10% of Grant funding
<p>Data</p>	<ul style="list-style-type: none"> • Institution owns the Research Data derived from Grant Research. • MMRF receives a non-exclusive royalty-free sublicensable license to the Grant Research Data.
<p>Publicity and Publication</p>	<ul style="list-style-type: none"> • MMRF to receive 30 days prior written notice of any publication. • MMRF acknowledgement in any publication shall state “Supported by a Research Grant from the Multiple Myeloma Research Foundation, Inc.” • The only database for public access for any published data resulting from the Grant Research shall be the MMRF Virtual Lab. • MMRF has right to publish Grant information on MMRF’s website or other material.
<p>Intellectual Property</p>	<ul style="list-style-type: none"> • Requirement to disclose Inventions derived from the Grant Research to MMRF. • Requirement to disclose revenue-generating opportunities to MMRF. • MMRF shall receive royalties from any Inventions at 20% of net income up to a cap of 5x the Grant Amount paid to MMRF annually.

	<ul style="list-style-type: none"> • MMRF right to audit Institution's relevant financial books.
<p>Indemnification</p>	<ul style="list-style-type: none"> • Mutual indemnification from and against any and all claims, liabilities, damages, losses, and expenses (including reasonable attorneys' fees) arising out of or resulting from the negligent acts, omissions, or willful misconduct of the Indemnifying Party in connection with this Grant.



**Multiple Myeloma Research Foundation
2026 Research Fellowship Program
Application Instructions**

A. General Requirements

a. Required Format: Applications must be in English using single-spaced text, half-inch margins, using either Arial or Times New Roman 11- or 12-point font. Page limitations must be observed for each section as described below.

b. Good Standing: Applications will only be accepted from research investigators who are currently in good standing with the MMRF. An applicant will automatically be considered to be in good standing unless they have failed to provide progress reports on prior MMRF-funded grants.

Note: Sections B – E must be completed in the template titled “Prerequisite Applicant Information” which is provided in Exhibit B of this document. Please download the template, complete each section and save the document, and then submit it as a single PDF file.

B. Abstract

This Section should contain the following:

- 1) General Audience Abstract: briefly describe your proposed project in 100 words or less using non-technical language (i.e., at a level that an eighth grader would understand).
- 2) Technical Abstract: briefly describe your proposed project in 100 words or less using technical language.

C. Biographical Sketch

This Section should contain the biographical sketches of the Principal Investigator and all key personnel. This must include any personnel who are referenced in the budget. Do not exceed two pages per biographical sketch.

D. Budget

Please provide a detailed budget and budget justification fully outlining specific needs for professional and technical staff and itemized supplies by category. Please see the definition of Permissible and Impermissible Costs in the above section on *Funds Available*.



All budget items should be explained under *Budget Justification*.

E. Other Research Support

Other support is defined as any specific funds or resources, whether governmental, non-governmental or institutional, available to the Principal Investigator (and the other key personnel named in the application) in direct support of their research endeavors. This should include active support and pending support.

Information regarding active or pending sources of support available to the Principal Investigator (and other key personnel named in the application), whether related to this application or not, is an important part of the review and award process and must be included.

Note: Sections F - G should be completed in the template titled “Application Template” which is provided in Exhibit C of this document. Complete each section in the template and submit it as a single PDF file.

F. Project Description

Limited to **5 pages**, but excluding necessary supporting materials such as references, figures, and tables (*see Section G regarding submission of supporting materials*). The project description should be presented in the following sequence:

- A) Specific Aims (approximately 0.5 pages)
- B) Scientific Background and Clinical Significance of Proposed Studies (approximately 1.0 pages)
- C) Previous Work or Preliminary Data (approximately 1.5 pages)
- D) Methods, Model Systems and Assays (approximately 1.0 pages)
- E) Plans for Clinical Application of Data (if applicable; approximately 0.5 pages)
- F) Resources and Environment including support from research mentor/sponsor (approximately 0.5 pages)

G. Supporting Materials (References, Figures and Tables)

Any referenced publications in the Project Description, Figures, and Tables should be submitted as materials in the Appendix and will not count against the five (5) page limit in Section F (Project Description).

Note: There is no template provided for Sections H – M. These documents need to be submitted as separate PDF files in an Appendix folder. The Appendix may be submitted as a



zipped folder containing all Appendix items. Please see each section for any specific instructions or notes.

H. Letter of Support (Required)

Candidates must include a letter of support with their application. This letter must be from a senior faculty Mentor who is active in the myeloma field, commenting on the qualifications and potential of the applicant and stating that they are able to provide an appropriate research environment and career guidance for the candidate.

I. Biohazards Statement (Required)

An institutional statement and assurances regarding potential biohazards and safeguards must be included. The Department of Environmental Health and Safety (or equivalent office) at most institutes and universities can provide the applicant with a letter stating that the laboratory and/or the applicant is in compliance with applicable laws. This is the document that should be submitted.

J. Clinical Research Statement (Required if applicable)

If applicable, clinical research protocols must be submitted as materials in the Appendix. Include IRB/Ethical Committee approval/compliance number or indicate pending and an anticipated approval date.

K. Laboratory Animals Statement (Required if applicable)

For projects which involve laboratory animals, the Institutional Animal Care and Use Committee (IACUC) Approval Date and Animal Welfare Assurance number must be given. Non-US applicants must submit approval documentation from their Animal Ethics Committee.

L. Request for Resource Support (Optional)

The MMRF may be able to provide access to external research resources and expertise through its network of collaborator institutions and investigators. Applicants who require access to novel or advanced research technologies and platforms, or expertise, in order to complete the research aims described in their application may request assistance from the MMRF to identify the required. Applicants requesting Resource Support must provide a brief description of their expected external technical or expertise needs (0.5 pages).

We strongly recommend that investigators contact the MMRF to discuss their resource needs prior to submission of their application. Investigators should contact both



Chaitanya (Chuck) Acharya, PhD and **Steven Foltz, PhD** via email at grants@themmrf.org to discuss resource requests.

M. Relevant Publications (Optional)

A set of the applicant's publication reprints which are relevant to the proposed project can be included. Please be aware that any password protection feature must be removed. Many articles when downloaded from journal sites contain password protection to prevent modifications of the document. Please note: if the password protection is not removed, reviewers will have difficulty in downloading your application. Applicants will be limited to five (5) publication reprints. Applications with more than five (5) publications will not be accepted. Submitting numerous large files adds to the download time of your application and can create complications when submitting the application materials via email.

Note: Applicants may either include all publications in one document as a Publication Appendix or submit each publication as a separate Appendix to the application. Include in the name of the document(s) or Appendix(s) the following: 1) Applicant's last name and 2) description of the document or appendix. For example: Smith_Publication_Appendix.PDF (one document with all publications) or Smith_Paper_on_Mouse_Model_X.PDF and Smith_Paper_on_Myeloma_Drug_Y.PDF, etc.

N. Signatures (Required)

The signature page is provided as a printable document and is the last step before submitting the application. Applicants should print the signature page, sign (applicant) and then have the appropriate institutional representatives sign the document; e.g., the Institute Signing Official and Finance Officials. Include the completed Signature page in the Appendix. **Please check with your institute's Office of Sponsored Programs, or equivalent, to ensure you are obtaining the appropriate signatures.**

O. Complete and Submit the Application

All applicants must submit a complete application via email by sending the package of application materials to grants@themmrf.org.

The application email should use the subject line "2026 MMRF Research Fellowship Application -- [Researcher Name and Institution]". The following three attachments must be included:

1. Prerequisite Applicant Information (single PDF)
2. Application Template (single PDF)
3. Appendix (zipped folder)
 - a. Letter of Support (required)



- b. Biohazards Statement (required)
- c. Clinical Research Statement (required if applicable)
- d. Laboratory Animals Statement (required if applicable)
- e. Request for Resource Support (optional)
- f. Relevant Publications (optional)
- g. Signatures (required)

NOTE: PAPER APPLICATIONS WILL NOT BE ACCEPTED. ALL APPLICATIONS MUST BE ELECTRONICALLY SUBMITTED BY 11:59 PM EDT ON JULY 15th, 2026. APPLICATIONS RECEIVED AFTER THIS DATE WILL NOT BE CONSIDERED.

P. Publicity, Exhibits and Publication.

- 1. Announcement and MMRF Publication of Award.** MMRF reserves the right to publicly announce that it has provided Sponsoring Institution and Principal Investigator a grant award and the amount of the grant. MMRF will ask for an abstract of the Grant Research to be conducted. The Sponsoring Institution shall obtain any internal approvals necessary to grant MMRF the right to use of its name, logo, and likeness prior to execution of this Grant Agreement. Sponsoring Institution shall not unreasonably withhold such approval.
- 2. Program Marketing.** The Sponsoring Institution and Principal Investigator hereby, as a condition to receiving Grant Funds, agree to participate in publicity activities, including, but not limited to, being interviewed for MMRF newsletters, press releases, and video as requested by the MMRF as well as acknowledge the grant award in Sponsoring Institution's donor marketing materials.
- 3. Prior Notification of Promotion, Presentation or Exhibition.** MMRF shall receive written notice from Principal Investigator at least thirty (30) days prior to any publication, exhibition or presentation relating to Grant Information (which notification shall include a copy of the materials intended for release, as well as the details of the information to be disclosed and the time, place and manner of such disclosure).
- 4. Credits.** All published works, including, but not limited to, on-line publications, exhibitions, presentations, marketing materials or other disclosures of Grant Information or summaries thereof by Sponsoring Institution or Principal Investigator must display the designation, "Supported by a Research Grant from the Multiple Myeloma Research Foundation (MMRF)."



5. **MMRF Publication of Results.** MMRF shall have the right to include published Grant Information results on its website or in other MMRF materials.

6. **Data Sharing.** MMRF is hereby granted an irrevocable, worldwide, non-exclusive, royalty free, sublicensable license to the de-identified (as defined by HIPAA) data and results generated in the performance of Grant Research to include in the MMRF data repository. Sponsoring Institution and Principal Investigator shall provide de-identified (as defined by HIPAA) data, Experimentals, and results of the Grant Research to MMRF in digital format for incorporation into data repository along with the Final Report. MMRF may incorporate into data repository de-identified (as defined by HIPAA) data, Experimentals, and results of the Grant Research received with the Final Report at the earlier of eighteen (18) months from receipt, or upon publication of the Grant Research by Sponsoring Institution or Principal Investigator. Sponsoring Institution and Principal Investigator agree that once MMRF has incorporated such de-identified (as defined by HIPAA) data, Experimentals, and results into the data repository, MMRF will have the unrestricted right to use, distribute, share, and publish the de-identified (as defined by HIPAA) data, Experimentals, and results.



EXHIBIT A

Patent, Intellectual Property and Technology Transfer Policy of the Multiple Myeloma Research Foundation, Inc.

1. **Disclosure and Assignment of Invention(s) by the Principal Investigator; Report to MMRF.**
 - (a) **Disclosure and Assignment of Invention(s) by Principal Investigator.** The Sponsoring Institution shall require the Principal Investigator and all other persons engaged in the Grant Research to promptly:
 - (i) disclose all Inventions to the Office of Technology (or the equivalent) of the Sponsoring Institution;
 - (ii) assign to the Sponsoring Institution all of their rights, title, and interest in and to all Inventions which are conceived, discovered, or reduced to practice by such person during the course of the Grant Research at the Sponsoring Institution;
 - (iii) require all such persons to cooperate fully with the Sponsoring Institution in pursuing legal protection for any Inventions or improvements thereto, including but not limited to providing assistance in filing and presenting any patent applications for or copyrights on such Inventions or improvements.
 - (b) **Reporting to MMRF.** Institution and/or Principal Investigator shall report any invention or lack thereof to MMRF on an annual basis on or about April 30th. Notwithstanding the foregoing, all Inventions shall be reported to MMRF in writing within three (3) months after their disclosure to the Sponsoring Institution.
2. **Sponsoring Institution's Duty to Decide on Protection of Invention and Notify MMRF.** Sponsoring Institution shall determine whether it will seek patent or other statutory protection for each Invention promptly after such Invention is disclosed to the Sponsoring Institution, and it shall promptly notify MMRF of its decision. Upon MMRF's request, Sponsoring Institution shall notify MMRF when documentation relating to the filing or assertion of rights has been published and are publicly available.
3. **Licensing of Invention by Sponsoring Institution.**
 - (a) **Notice to MMRF of Possible Revenue-Generating Agreement.** If the Sponsoring Institution contemplates entering into a license, assignment, or other revenue-generating agreement relating to the Invention, the Sponsoring Institution shall give MMRF written notice thereof prior to execution.
 - (b) **Requirements for Such Agreement.** Any agreements referred to in Section 3(a) of this Exhibit relating to Inventions shall be entered into by the Sponsoring Institution and/or the Principal Investigator on an arm's-length



basis with the licensee, assignee, or transferee as the case may be.

4. **Participation in Income.** MMRF shall have the right to participate in the income derived from any Invention, unless MMRF explicitly waives such right in writing, and the parties hereby agree that no provision of the Agreement shall constitute such a waiver. This right to participate shall include the sharing of licensing fees and royalties and any other consideration derived from an Invention by Sponsoring Institution and/or Principal Investigator at a rate of twenty percent (20%) of net income up to a cap of five (5) times the grant amount funded by MMRF. MMRF's participation in income hereunder shall be paid on a calendar yearly basis and shall be accompanied by copies of all invoices sent by Sponsoring Institution to its licensees, assignees, and/or transferees as the case may be. MMRF shall have the right to audit Sponsoring Institution's books with advance written notice and records no more frequently than one time per year to verify the payments hereunder, with the understanding that access to such information shall be limited by any obligations of confidentiality that the Sponsoring Institution has to its licensees, assignees or transferees.

EXHIBIT B
Prerequisite Applicant Information

Applicant Name (Last, First, Middle): _____

Abstracts

General Audience Abstract: Briefly describe your proposed project in 100 words or less. Be sure to use language that can be easily understood by a general audience.

Technical Abstract: Briefly describe your proposed project in 100 words or less.

BIOGRAPHICAL SKETCH

Provide the following information for all key personnel.

DO NOT EXCEED TWO (2) PAGES.

NAME	POSITION TITLE
-------------	-----------------------

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.*)

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY

A. Positions and Honors.

B. Selected peer-reviewed publications (in chronological order).

Applicant Name (Last, First, Middle):

DETAILED BUDGET FOR THE YEAR***						FROM	THROUGH
PERSONNEL			% EFFORT ON PROJ.	INST. BASE SALARY	DOLLAR AMOUNT REQUESTED <i>(omit cents)</i>		
NAME	ROLE ON PROJECT				SALARY REQUESTED	FRINGE BENEFITS	TOTAL
SUBTOTALS →							
EQUIPMENT <i>(Itemize)</i>							
SUPPLIES <i>(Itemize by category)</i>							
TRAVEL <i>(not to exceed \$1500)</i>							
OTHER EXPENSES <i>(Itemize by category)</i>							
TOTAL DIRECT COSTS (TDC) FOR INITIAL BUDGET PERIOD						\$	
TOTAL FACILITIES AND ADMINISTRATIVE (INDIRECT) COSTS FOR INITIAL BUDGET PERIOD (MAXIMUM 10% of TDC)						\$	
TOTAL COSTS FOR INITIAL BUDGET PERIOD						\$	

*** Please refer to Policies & Procedures regarding permissible and non-permissible costs.

Applicant Name (Last, First, Middle):

BUDGET JUSTIFICATION. Follow the budget justification instructions. **Do not exceed 2 pages.**

Other Research Support

List other research support available to the principal investigator (and other key personnel listed in the application).

Applicant Name (Last, First, Middle):

EXHIBIT C
Application Template

Do not exceed 5 pages.

- A.** Specific Aims (0.5 pages)
- B.** Scientific Background and Clinical Significance of Proposed Studies (1.0 pages)
- C.** Previous Work/Preliminary Data (1.5 pages)
- D.** Methods, Model Systems and Assays Proposed (1.0 pages)
- E.** Plans for Clinical Application of Data (0.5 pages)
- F.** Resources and Environment (0.5 pages)

Applicant Name (Last, First, Middle):

Supporting Materials

References:

Figures:

Tables:

Applicant Name (Last, First, Middle):

MMRF Research Fellowship Program

Signatures Page

Project title:		
Principal Investigator (Name, Title, Institution)	Signature	Date
Co-Investigator(s) (Name, Title, Institution)	Signature	Date
Institute Signing Official (Name, Title, Institution)	Signature	Date